Oral IL-23 Inhibitor Effective in Psoriasis The NEJM has published the results of the FRONTIER 1 trial demonstrating the efficacy of JNJ-77242113, an oral interleukin-23 (IL-23) receptor antagonist peptide, in patients with psoriasis (PSO). https://t.co/NRK8LnM5zp https://t.co/FnWEze976O